Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction

Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.